Kodiak Sciences Inc (KOD) Dividend History

Kodiak Sciences Inc (KOD) is a biotechnology company focused on developing ophthalmology and CNS therapies using its proprietary antibody and antibody conjugate platform. Established to address serious retinal diseases, it works on a range of innovative treatments aimed at unmet medical needs in eye health.

1200 Page Mill Rd, Palo Alto, CA, 94304
Phone: 650-281-0850
Website: https://www.kodiak.com

Dividend History

Kodiak Sciences Inc currently does not pay dividends

Company News

  • The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.

    GlobeNewswire Inc.
    Featured Companies: ABBV ALC PFE REGN
  • Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

    Zacks Investment Research
    Featured Companies: ALXO ANVS CGEN
  • Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Xilio Therapeutics, Inc. (NASDAQ: XLO) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares climbed 80% to $1.5395. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers. Ontrak, Inc. (NASDAQ: OTRK) gained 55% to $0.9239. Binah Capital Group, Inc. (NASDAQ: BCG) gained 48% to $14.05 after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Allego N.V. (NASDAQ: ALLG) rose 32.8% to $1.7650. Akanda Corp. (NASDAQ: AKAN) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Destiny Tech100 Inc. (NASDAQ: DXYZ) rose 26% to $22.15. REX American Resources Corporation (NYSE: REX) gained 23.2% to $54.15 following upbeat earnings. Nutriband Inc. (NASDAQ: NTRB) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Summit Therapeutics Inc. (NASDAQ: ...

    Benzinga
  • U.S. stocks finish higher on Monday, following the best week for equities in 2023.

    MarketWatch
    Featured Companies: BMBL COMP DIS DJIA PARA TSLA UBER VRTX
  • An analyst downgrade is weighing on the drugmaker's stock price today.

    The Motley Fool
    Featured Companies: XBI
Page data last updated 07/23/2025 14:45:41 UTC